Stock Analysis on Net
Stock Analysis on Net

Allergan PLC (NYSE:AGN)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Paying user area

Try for free

Allergan PLC pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Allergan PLC, consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Accrued third-party rebates
Litigation-related reserves and legal fees
Accrued payroll and related benefits
Accrued returns and other allowances
Accrued R&D expenditures
Interest payable
Royalties payable
Accrued pharmaceutical fees
Accrued severance, retention and other shutdown costs
Accrued non-provision taxes
Accrued selling and marketing expenditures
Current portion of contingent consideration obligations
Dividends payable
Other accrued expenses
Accrued expenses
Accounts payable
Accounts payable and accrued expenses
Income taxes payable
Current portion of long-term debt and capital leases
Current portion of lease liability, operating
Current liabilities held for sale
Current liabilities
Long-term debt and capital leases, excluding current portion
Lease liability, operating, excluding current portion
Acquisition related contingent consideration liabilities
Long-term pension and post retirement liability
Legacy Allergan deferred executive compensation
Accrued R&D milestone
Long-term contractual obligations
Deferred revenue
Product warranties
Long-term severance and restructuring liabilities
Other long-term liabilities
Other long-term liabilities
Long-term liabilities held for sale
Other taxes payable
Deferred tax liabilities
Long-term liabilities
Total liabilities
Preferred shares, $0.0001 par value per share
Ordinary shares; $0.0001 par value per share
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income (loss)
Shareholders’ equity
Noncontrolling interest
Total equity
Total liabilities and equity

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

Accrued Third-Party Rebates
There is a consistent increase in accrued third-party rebates from 1,281,600 thousand USD in 2015 to 2,001,800 thousand USD in 2019, indicating growing obligations in this category over the period.
Litigation-Related Reserves and Legal Fees
These reserves declined from 213,500 thousand USD in 2015 to 78,300 thousand USD in 2017, but surged sharply to 1,250,700 thousand USD in 2019, which suggests increased legal contingencies or settlements in the latest year.
Accrued Payroll and Related Benefits
Accrued payroll increased steadily, from 409,700 thousand USD in 2015 to 830,300 thousand USD in 2019, reflecting higher payroll-related liabilities or workforce growth.
Accrued Returns and Other Allowances
This category showed a gradual rise, nearly doubling from 288,400 thousand USD in 2015 to 596,700 thousand USD in 2019, signaling increasing expected returns or allowances.
Accrued R&D Expenditures
Accrued R&D expenses dropped sharply after 2015 (384,100 thousand USD) to a low of 154,000 thousand USD in 2016 but fluctuated afterwards, ending at 184,800 thousand USD in 2019, reflecting variability in R&D investment timing or recognition.
Interest Payable
Interest payable declined steadily from 312,000 thousand USD in 2015 to 189,500 thousand USD in 2019, possibly due to reduced interest expenses or changes in debt structure.
Royalties Payable
Royalties payable exhibited an overall upward trend, reaching 216,900 thousand USD in 2019 from 126,900 thousand USD in 2015, which may reflect increased royalty obligations linked to product sales or licensing agreements.
Accrued Pharmaceutical Fees
These fees declined from 162,200 thousand USD in 2015 to 125,900 thousand USD in 2019, indicating reduced accrued pharmaceutical-related liabilities over time.
Accrued Severance, Retention, and Other Shutdown Costs
There was a significant reduction in this liability from 110,400 thousand USD in 2015 to 12,700 thousand USD in 2019, suggesting a decrease in restructuring or shutdown activities.
Accrued Non-Provision Taxes
These accrued taxes dropped sharply from 100,300 thousand USD in 2015 to 64,600 thousand USD in 2019, indicating lower accrued tax liabilities outside of provisions.
Accrued Selling and Marketing Expenditures
There was a notable decline from 127,200 thousand USD in 2015 to around 61,300 thousand USD by 2019, demonstrating reduced accruing marketing expenses.
Current Portion of Contingent Consideration Obligations
This liability showed volatility, peaking at 511,000 thousand USD in 2016 before falling sharply to 12,100 thousand USD in 2019, suggesting settlements or reclassifications of contingent obligations.
Dividends Payable
Dividends payable decreased dramatically from 23,900 thousand USD in 2015 to just 1,100 thousand USD in 2019, pointing at lower dividend payments or changes in dividend timing.
Other Accrued Expenses
Other accrued expenses increased significantly to 1,192,600 thousand USD in 2017, from 360,000 thousand USD in 2015, before falling to 409,900 thousand USD in 2019, indicating varied accruals over the years.
Total Accrued Expenses
Overall accrued expenses rose from 3,980,100 thousand USD in 2015 to 5,958,300 thousand USD in 2019, revealing increased short-term accrued liabilities.
Accounts Payable
Accounts payable fluctuated but showed an upward trend from 369,400 thousand USD in 2015 to 390,400 thousand USD in 2019, indicating slightly higher payable balances.
Combined Accounts Payable and Accrued Expenses
This combined liability increased from 4,349,500 thousand USD in 2015 to 6,348,700 thousand USD in 2019, confirming a growth in short-term obligations.
Income Taxes Payable
Income taxes payable remained relatively stable with a slight decrease from 54,200 thousand USD in 2015 to 65,100 thousand USD in 2019, showing minor fluctuations.
Current Portion of Long-Term Debt and Capital Leases
This amount showed notable volatility, peaking at 4,231,800 thousand USD in 2017, dropping to 868,300 thousand USD in 2018, then rising again to 4,532,500 thousand USD in 2019, indicating refinancing activities or reclassifications.
Current Portion of Lease Liability
Data appears only for 2019, showing 124,400 thousand USD, suggesting the adoption of new lease accounting standards or newly recognized lease liabilities.
Current Liabilities Held for Sale
This liability was reported only in 2015 at 1,491,800 thousand USD, implying disposal or completion of held-for-sale transactions thereafter.
Total Current Liabilities
Current liabilities present irregular trends with a decrease in 2018 to 5,727,900 thousand USD from a high of 9,848,100 thousand USD in 2017, followed by a sharp increase to 11,070,700 thousand USD in 2019, reflecting fluctuating short-term obligations and possibly shifts in classification.
Long-Term Debt and Capital Leases (Excluding Current Portion)
There is a consistent decrease from 40,293,400 thousand USD in 2015 to 18,116,500 thousand USD in 2019, indicating significant debt repayments or refinancing reducing long-term debt obligations.
Lease Liability Excluding Current Portion
Reported at 446,100 thousand USD in 2019 only, likely reflecting implementation of updated lease accounting rules.
Acquisition Related Contingent Consideration Liabilities
These liabilities decreased from 788,100 thousand USD in 2015 to 377,300 thousand USD in 2019, indicating resolution or reduction of contingent acquisition obligations over time.
Long-Term Pension and Post Retirement Liability
This liability decreased steadily from 222,100 thousand USD in 2015 to 144,100 thousand USD in 2019, reflecting possible plan settlements or reduced pension obligations.
Legacy Deferred Executive Compensation
These liabilities declined gradually from 117,900 thousand USD in 2015 to 89,200 thousand USD in 2019, suggesting progressive payments or adjustments.
Accrued R&D Milestone
Reported only in 2018 and 2019 at 75,000 thousand USD each year, suggesting milestone-related R&D commitments recognized in these periods.
Long-Term Contractual Obligations
Showed an increase from 26,400 thousand USD in 2015 to a peak of 45,200 thousand USD in 2017, before slightly declining, reflecting contractual commitments fluctuating.
Deferred Revenue
Deferred revenue experienced an increase to 37,900 thousand USD in 2017 before declining to 26,600 thousand USD in 2019, indicating timing variations in unearned revenue recognition.
Product Warranties
Maintained relative stability between 27,900 and 29,200 thousand USD, showing consistent warranty liabilities.
Long-Term Severance and Restructuring Liabilities
These decreased from 34,900 thousand USD in 2015 to 10,800 thousand USD in 2019, suggesting reduced restructuring activities.
Other Long-Term Liabilities
One category shows an increase from 26,000 thousand USD in 2015 to 92,000 thousand USD in 2018, falling back to 48,700 thousand USD in 2019, while another larger category declined steadily from 1,262,000 thousand USD in 2015 to 800,900 thousand USD in 2019, both indicating fluctuations in miscellaneous long-term obligations.
Long-Term Liabilities Held for Sale
Reported only in 2015 at 580,100 thousand USD, with no subsequent entries, consistent with disposal or completion of held-for-sale transactions.
Other Taxes Payable
There is a clear increasing trend from 801,900 thousand USD in 2015 to 1,704,800 thousand USD in 2019, indicating growing tax-related liabilities.
Deferred Tax Liabilities
Deferred tax liabilities saw significant fluctuations, rising from 7,985,700 thousand USD in 2015 to a peak of 12,969,100 thousand USD in 2016, then decreasing steadily to 4,363,700 thousand USD in 2019, reflecting changes in temporary differences and tax planning strategies.
Total Long-Term Liabilities
Displayed a continuous decrease from 50,923,100 thousand USD in 2015 to 25,432,000 thousand USD in 2019, signifying debt reductions and lower long-term obligations.
Total Liabilities
Total liabilities declined markedly from 59,251,400 thousand USD in 2015 to 36,502,700 thousand USD in 2019, primarily driven by decreases in long-term debt and other obligations outweighing current liabilities’ rise.
Preferred Shares
Preferred shares remained constant at 4,929,700 thousand USD through 2017, with no data in later years, suggesting possible redemption or reclassification.
Additional Paid-In Capital
Decreased from 68,508,300 thousand USD in 2015 to 55,974,900 thousand USD in 2019, indicating possible share repurchases or capital adjustments.
Retained Earnings
Retained earnings experienced a peak of 18,342,500 thousand USD in 2016, but subsequently declined sharply to 991,500 thousand USD in 2019, which may reflect net losses, dividends, or other equity changes.
Accumulated Other Comprehensive Income (Loss)
This balance moved from a negative 494,100 thousand USD in 2015 to a positive 1,207,200 thousand USD in 2019, showing improvements in unrealized gains or other comprehensive income components.
Shareholders’ Equity
Shareholders’ equity declined from 76,591,400 thousand USD in 2015 to 58,173,600 thousand USD in 2019, indicating reductions in net assets possibly due to losses, dividend payments, or capital transactions.
Noncontrolling Interest
Gradually increased from a negative 2,100 thousand USD in 2015 to 22,800 thousand USD in 2019, reflecting changes in ownership interests.
Total Equity
Total equity followed a downward trend from 76,589,300 thousand USD in 2015 to 58,196,400 thousand USD in 2019, consistent with decreases in shareholders’ equity and shifts in noncontrolling interests.
Total Liabilities and Equity
The aggregate of liabilities and equity showed a steady decline from 135,840,700 thousand USD in 2015 to 94,699,100 thousand USD in 2019, reflecting overall balance sheet contraction possibly from asset sales, debt reductions, or other financial restructuring.